Company profile: Dexcom
1.1 - Company Overview
Company description
- Provider of continuous glucose monitoring systems and data services for diabetes management, developing, manufacturing and distributing Dexcom G7 (real-time readings and alerts, compatible with Apple Watch), Dexcom G6 (for users 2+), and the OTC Stelo Glucose Biosensor System for adults not on insulin, plus Dexcom Clarity for glucose data analysis and Dexcom Follow/Share for remote data sharing.
Products and services
- Dexcom Clarity: An analytics-driven data service that processes and analyzes glucose data from Dexcom devices to help users manage diabetes
- Dexcom G6: An age-inclusive continuous glucose monitoring system offering real-time glucose monitoring and alerts, suitable for users aged 2 and above for day-to-day diabetes tracking
- Dexcom G7: A device-compatible continuous glucose monitoring system delivering real-time glucose readings and alerts, working with various devices including Apple Watch for continuous diabetes management
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Dexcom
GI Dynamics
HQ: United States
Website
- Description: Provider of endoscopically delivered medical devices for managing type 2 diabetes, obesity, and related metabolic diseases, including RESET, which creates a barrier in the small intestine to improve insulin resistance and glycemic control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GI Dynamics company profile →
Sensulin
HQ: United States
Website
- Description: Provider of diabetes drug discovery focused on a once-a-day glucose-responsive insulin for type 1 and type 2 diabetes, designed to reduce hypoglycemia risk and long-term complications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sensulin company profile →
Fractyl Health
HQ: United States
Website
- Description: Provider of curative therapies for metabolic diseases, including Revita, a therapy designed to modify duodenal dysfunction via hydrothermal ablation to restore metabolic health, and Rejuva, a preclinical AAV gene therapy platform aimed at improving islet function for long-term remission of T2D and obesity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fractyl Health company profile →
CanAm Care
HQ: United States
Website
- Description: Provider of medical equipment and devices as a healthcare company, engaged in manufacturing and retail.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CanAm Care company profile →
Intarcia
HQ: United States
Website
- Description: Provider of long-term therapies for chronic diseases, offering the MEDICITM Drug Delivery System for twice-yearly subcutaneous osmotic implants, ITCA 650 (twice-yearly exenatide implant) for type 2 diabetes, and an Ionic Liquid Platform converting injectable biologics and peptides into oral therapies; pipeline includes i2o-105s (long-acting GLP-1 receptor agonist), i2o-107 (long-acting amylin), and i2o-110 (dual agonist) for type 2 diabetes, obesity, and NASH.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Intarcia company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Dexcom
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Dexcom
2.2 - Growth funds investing in similar companies to Dexcom
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Dexcom
4.2 - Public trading comparable groups for Dexcom
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →